Air Care Tablet 10mg (Solifenacin Succinate)

Adult dose

The usual recommended dose for adults, including elderly patients, is 5mg once daily. If necessary, the dose may be increased to a maximum of 10mg once daily. This medicine may be taken with or without food and should be swallowed whole with water. Dosage adjustment is required for the following patients. 1. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Caution is required in patients with severe renal impairment (creatinine clearance≤30ml/min), and the dose should not exceed 5mg once daily. 2. Patients with hepatic impairment: No dose adjustment is necessary for patients with mild hepatic impairment. Caution is required in patients with moderate hepatic impairment (Child-Pugh class B), and the dose should not exceed 5mg once daily. 3. Patients receiving a strong cytochrome P450 3A4 (CYP3A4) inhibitor: For patients receiving ketoconazole or another strong CYP3A4 inhibitor (e.g., ritonavir, nelfinavir, itraconazole), limit the maximum daily dose to 5mg.

This medication is used to treat bladder hyperactivity and urinary disorders. Do not use this medication in patients with urinary retention symptoms or severe gastrointestinal diseases, myasthenia gravis, or narrow-angle glaucoma. Additionally, it is safe not to administer to patients undergoing dialysis, those with severe liver impairment, severe kidney impairment, or specific genetic metabolic disorders. Caution should be exercised when administering this medication to patients at risk of urinary retention, gastrointestinal obstructive diseases, those at risk of decreased gastrointestinal motility, and patients with severe kidney impairment or moderate liver impairment. This medication can cause common side effects associated with antimuscarinic drugs such as dry mouth, constipation, and blurred vision, especially at higher doses these side effects may occur more often. Serious gastrointestinal adverse reactions or angioedema, anaphylactic reactions have been reported. If these symptoms occur, immediately discontinue the medication and seek medical attention. This medication may require caution during driving or machinery operation, as symptoms such as drowsiness or blurred vision may occur. The effects may be enhanced or side effects may be worsened when combined with other anticholinergic medications, and it may reduce the effectiveness of certain gastrointestinal motility agents. This medication is metabolized by the CYP3A4 enzyme, so the dosage should be limited when used with strong CYP3A4 inhibitors, and co-administration should be avoided in patients with severe kidney or liver impairment. The safety for pregnant women has not been established; therefore, it should be administered with caution to pregnant women, and it is advisable for breastfeeding women to avoid using this medication. The safety and efficacy of this medication in children have not been established, so it should not be used in pediatric patients. In cases of overdose, symptoms such as headache, dizziness, drowsiness, and blurred vision may occur, and appropriate emergency measures are needed for severe symptoms. Special caution is needed for patients with heart disease or a risk of QT prolongation.

• Dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• nausea
• indigestion
• abdominal pain
• vomiting
• urinary tract infection

This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to store it at room temperature between 1 and 30 degrees Celsius.

Appearance

Bright pink round film-coated tablets

Package unit

100 tablets (10 tablets/PTP X 10)